TICKERNERD
Menu
LXRXLXRXHealthcare · Biotechnology

LXRX Stock Forecast: Lexicon Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$2.00
−0.99% on the day

The 5 Wall Street analysts covering Lexicon Pharmaceuticals, Inc. hold a median 12-month price target of $3.1 — +55.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 68 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$889.9M
Ticker Nerd rank
68 / 100
Median analyst target
$3.10
Analysts covering
5
Revenue$692K−97.6% y/y
Operating income−$26.5M
Net income−$31.8M
Free cash flow−$9.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−11.5%
1M
−17.7%
YTD
+73.9%
1Y
+80.2%
From 52W high
−24.2%
From 52W low
+83.5%
$1.09
$2.64
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LXRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Lexicon Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
68 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
90
Quality
88
Value
76
Growth
49
Size
46
Issuance
46
Revisions
45
Volatility
44
Accruals
43

Momentum (90): The shares have been drifting up relative to others.

Accruals (43): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LXRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LXRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00Oct 25Jan 26Apr 26Jul 26LXRXHigh $6.00Median $3.10Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
3 Buy2 Hold0 Sell
Low $2.00Median $3.10High $6.00

The green dot is the last close — the median target sits +55.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 May 2026CitigroupMaintainsBuy$2.30 → $3.10
23 Mar 2026HC Wainwright & Co.ReiteratesBuy—
10 Mar 2026CitigroupMaintainsBuy—
5 Mar 2026HC Wainwright & Co.MaintainsBuy—
2 Sept 2025HC Wainwright & Co.ReiteratesBuy—
7 Aug 2025CitigroupMaintainsBuy—
24 June 2025HC Wainwright & Co.ReiteratesBuy—
28 Mar 2025HC Wainwright & Co.ReiteratesBuy—
7 Mar 2025HC Wainwright & Co.ReiteratesBuy—
7 Mar 2025NeedhamReiteratesHold—
7 Mar 2025Piper SandlerMaintainsOverweight—
4 Mar 2025Leerink PartnersDowngradeMarket Perform—
3 Mar 2025HC Wainwright & Co.ReiteratesBuy—
3 Mar 2025NeedhamReiteratesHold—
29 Jan 2025HC Wainwright & Co.ReiteratesBuy—
29 Jan 2025NeedhamReiteratesHold—
23 Dec 2024NeedhamReiteratesHold—
25 Nov 2024NeedhamReiteratesHold—
22 Nov 2024NeedhamReiteratesHold—
13 Nov 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LXRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

LXRX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Lexicon Pharmaceuticals, Inc. returned +80.2% against +17.5% for the S&P 500, dividends included.

LXRX vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180200220Oct 25Jan 26Apr 26Jul 26LXRXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LXRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Lexicon Pharmaceuticals, Inc. (LXRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−14.3×

Cheaper than 94% of US stocks

Price / sales
21.5×

Cheaper than 9% of US stocks

Price / book
5.1×

Cheaper than 20% of US stocks

EV / EBITDA
−14.0×

Cheaper than 87% of US stocks

Growth & margins
Revenue growth (YoY)
−97.6%

Higher than 2% of US stocks

Earnings growth (YoY)
−97.6%

Higher than 2% of US stocks

Gross margin
94.4%

Higher than 98% of US stocks

Operating margin
−3835.3%

Higher than 3% of US stocks

Net margin
−147.4%

Higher than 4% of US stocks

Returns & dividend
Return on equity
−40.2%

Higher than 24% of US stocks

Return on assets
−14.3%

Higher than 23% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Lexicon Pharmaceuticals, Inc. (LXRX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Lexicon Pharmaceuticals, Inc. has a market value of $889.9M and an enterprise value of $758.5M.

  • Revenue in the twelve months to 30 June 2026: $41.5M. The latest quarter shrank 97.6% year on year.

  • Net income over the same four quarters: −$61.1M, a −147.4% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.15.

  • Free cash flow in the twelve months to 30 June 2026: −$65.0M.

  • Shares outstanding: 444.9M.

  • Trailing P/E: −14.3×; forward P/E: −10.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Lexicon Pharmaceuticals, Inc. employs 81 people — $512K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

LXRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LXRXLexicon Pharmaceuticals, Inc.$889.9M
68
OLMAOlema Pharmaceuticals, Inc.$890.7M
30
WVEWave Life Sciences, Inc.$883.0M
14
DSGNDesign Therapeutics, Inc.$902.3M
65
RIGLRigel Pharmaceuticals, Inc.$874.0M
77
ARDXArdelyx, Inc.$869.8M
50
SLDBSolid Biosciences, Inc.$914.6M
43

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Lexicon Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LXRX news & analysis

Lexicon Pharmaceuticals, Inc. (LXRX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha · 9 Sept 2026neutral

Lexicon Pharmaceuticals presented at Citigroup's Biopharma Back to School Summit 2026, with a transcript of the presentation published by Seeking Alpha. The item reflects a corporate presentation event at an industry conference.

Why it matters — A Lexicon investor would care because the presentation transcript may offer insight into the company's strategy and updates directly from management at a major industry conference.

Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences

GlobeNewsWire · 1 Sept 2026neutral

Lexicon Pharmaceuticals announced that company management will present at three upcoming investor conferences taking place in New York, NY, according to a September 1, 2026 press release. The company made the announcement from its headquarters in The Woodlands, Texas.

Why it matters — LXRX watchers would care because management presentations at investor conferences offer opportunities for the company to communicate its business directly to the investment community.

Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure

GlobeNewsWire · 31 Aug 2026positive

Lexicon announced a new post hoc analysis of the SOLOIST-WHF trial showing sotagliflozin produced consistent results across baseline blood pressure levels in patients with recent worsening heart failure. The findings were presented at ESC Congress 2026 and simultaneously published in JACC: Heart Failure.

Why it matters — The analysis broadens the evidence supporting sotagliflozin's efficacy in a wider range of heart failure patients, which LXRX watchers would view as a favorable development for the drug.

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

GlobeNewsWire · 24 Aug 2026positive

Lexicon Pharmaceuticals received its third $10 million milestone payment from Novo Nordisk after LX9851, a first-in-class oral non-incretin candidate for obesity and associated metabolic disorders, achieved a key Phase 1 development milestone.

Why it matters — A LXRX watcher would care because the payment reflects progress on the partnered LX9851 program with Novo Nordisk and its associated milestone revenues for Lexicon.

Lexicon Pharmaceuticals Edging Closer To 'Go Time' On Multiple Late-Stage Assets

Seeking Alpha · 19 Aug 2026positive

Lexicon Pharmaceuticals is approaching multiple potential value-driving milestones for sotagliflozin, including the pivotal SONATA-HCM Phase III readout expected in 2027 and an NDA re-filing for type 1 diabetes before year-end. The article notes that regulatory and commercialization risks may outweigh clinical risk, particularly for the T1D indication.

Why it matters — A Lexicon watcher would care because the upcoming late-stage data readout and regulatory filing represent key catalysts for the company's primary value driver, sotagliflozin.

FAQ

Frequently asked questions about LXRX stock

What is the LXRX stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Lexicon Pharmaceuticals, Inc. have a median 12-month price target of $3.1, with estimates ranging from $2 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LXRX stock a buy right now?

Of the 5 analysts covering Lexicon Pharmaceuticals, Inc., 3 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lexicon Pharmaceuticals, Inc. 68 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LXRX?

As at 12 Sept 2026, Lexicon Pharmaceuticals, Inc. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (90 of 100).

Will LXRX stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +55.0% from the last close, and Ticker Nerd's factor model ranks Lexicon Pharmaceuticals, Inc. 68 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LXRX stock forecast for 2030?

No analyst covering Lexicon Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LXRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $6 over the next 12 months.

How has LXRX stock performed over the past year?

Lexicon Pharmaceuticals, Inc. returned +80.2% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Lexicon Pharmaceuticals, Inc. do?

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for human disease.

What is the latest news on LXRX?

The most recent item we track (Seeking Alpha, 9 Sept 2026): "Lexicon Pharmaceuticals, Inc. (LXRX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript". Lexicon Pharmaceuticals presented at Citigroup's Biopharma Back to School Summit 2026, with a transcript of the presentation published by Seeking Alpha. The item reflects a corporate presentation event at an industry conference.

Company

About Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for human disease. The company’s current portfolio centers on therapies for cardiometabolic disorders, neuropathic pain, and other chronic conditions, with products and candidates spanning commercial, clinical, and preclinical stages. Its marketed medicine INPEFA (sotagliflozin) is used in cardiometabolic care, while development programs include pilavapadin for neuropathic pain and LX9851 for obesity and related metabolic disorders. Lexicon Pharmaceuticals also applies its gene-science and target-biology expertise to advance drug candidates aimed at genetically defined pathways, reflecting a research-driven model that links discovery with commercialization. Headquartered in The Woodlands, Texas, Lexicon Pharmaceuticals serves the specialty pharmaceutical market through a focused pipeline designed for patients with serious, long-term medical needs.

CEO Dr. Michael S. Exton Ph.D. · 81 employees · United States · https://www.lexpharma.com